Introduction
Osteoarthritis is the most frequent chronic joint disease causing pain and disability. Besides biomechanical mechanisms, the pathogenesis of osteoarthritis (OA) may involve inflammation, vascular alterations and dysregulation of lipid metabolism (Figure) . Statins are drugs capable of modulating many of these different processes and therefore may have the potential to act as disease modifying drugs for osteoarthritis. In this study we hypothesized that statins decrease incidence and progression of knee and hip OA. To test this hypothesis, we used a large population cohort study.
Methods 2974 subjects of the Rotterdam Study (a population-based cohort study), aged 55 years and older and of which 6 years of follow-up was available, were included in this study. X-rays of the knee and the hip were obtained at baseline and follow-up (mean follow-up 6.3 years), and were scored with the Kellgren & Lawrence score (0=absent OA, 1=doubtful OA, 2=mild OA, 3=moderate OA, 4=severe OA, 5= prosthesis). Incidence of OA was defined as a Kellgren & Lawrence score of 0 or 1 at baseline and a score of 2 or more at follow-up. Progression of OA was specified as a Kellgren & Lawrence score of 1, 2 or 3 at baseline and increase of 1 or more at follow-up. Information on statin use during follow-up was obtained from detailed computerized pharmacy data. Use of statins was defined as the daily use of 50% or more of recommended dose and this for a period of 100 days or more. Data on potential confounding variables such as age, gender, body mass index, diabetes mellitus, arterial hypertension, peripheral artery disease, bone mineral density and total cholesterol level were collected. When these variables showed an association (p< 0.2) with outcome as well with statin use, they were added to the model. Odd ratios, p values and 95% confidence intervals (CI) were calculated for the association between statin use and incidence or progression of OA in a multivariable logistic model adjusting for confounders and making use of generalized estimated equation techniques to account for correlation between left and right side within persons.
Results
In the 2974 subjects, of which 1277 men and 1697 women, osteoarthritis (Kellgren & Lawrence score of 2 or more) was present in 546 knees (15%) and 323 hips (6.1%) at baseline and in 696 knees (19.4%) and 521 hips (9%) at follow-up. Incidence of left or right knee osteoarthritis in the study population was 2.9% and progression was 4.2%. 3.1% of the knees with doubtful, mild or moderate osteoarthritis (Kellgren and Lawrence score of 1, 2 or 3 showed progression of osteoarthritis, while this was 4.0% for the hip joints. 393 (13.2%) subjects were defined as statin users. The average days of use was 164.21 days (SD 496.47 ) and the average percentage of daily recommended dose was 0.13% (SD 0.36). Confounding variables for knee osteoarthritis and statin use included body mass index, bone mineral density, diabetes mellitus and plasma total cholesterol/HDL ratio. For the outcome values of hip osteoarthritis, odd ratios were adjusted for age, smoking, bone mineral density, plasma total cholesterol/HDL ratio and arterial hypertension. The use of statins is associated with a reduction of both incidence (OR 0.43, p=0.02 ) and progression of knee osteoarthritis (OR 0.47, p=0 .02) after adjustment for confounding variables (Table 1 ). In the hip joint, no associations were found for incidence (OR 0.85, ) and progression (OR 1.01, 95% CI 0.64 -1.60) ( Table 2) . 
